Evidence map›Paper›PMID 40540352›Full record

ReviewJournal of the American Society of Nephrology : JASN2025

Endothelial Progenitor Cells: Disease Markers and Potential Therapy in Kidney Disease.

Shahd Al Heijani, Mohamed Naim Khalil, Salsabil Haque, LaTonya J Hickson, Amir Lerman, Lilach O Lerman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shahd Al HeijaniDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0009-0007-5829-9761
Mohamed Naim KhalilCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.ORCID 0009-0001-5504-3476
Salsabil HaqueCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.ORCID 0009-0002-3930-2500
LaTonya J HicksonDivision of Nephrology and Hypertension, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-7485-336
Amir LermanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-9446-5313
Lilach O LermanDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-3271-3887

Funding

NHLBI NIH HHS HL158691NIA NIH HHS AG062104NIA NIH HHS AG076537NIDDK NIH HHS DK120292NIDDK NIH HHS DK122734
6 · The paper itself

Abstract

Endothelial progenitor cells (EPCs) constitute a promising focus for research in regenerative medicine. These cells originate from the bone marrow and other circulating hematopoietic cells and regulate tissue regeneration and vascular integrity. EPC mobilization serves for neovascularization and re-endothelialization after injury in multiple organ systems, including the renal and cardiovascular systems. Both their number and function may vary in disease states such as CKD, depending on severity, comorbid conditions, and other factors. Therefore, circulating EPC count and function have been proposed as markers for vascular health, and their mobilization or replenishment may offer a potential therapy. Delivery of EPCs has shown success in repairing injured kidneys in animal models of both chronic and AKIs. This approach may be limited by EPC heterogeneity and incomplete characterization that may be addressed by standardization, engineering, or combination with other therapies. The aim of this article was to review the current state and recent advances in our understanding of the role of EPCs in homeostasis and conditions that may lead to their dysregulation in kidney diseases.

Indexed as

Endothelial Progenitor CellsKidney DiseasesAnimalsBiomarkersHumansRenal Insufficiency, ChronicBiomarkersendothelial cellskidney disease

Identifiers

PMID40540352
PMCPMC12591685

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.